3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cyclophosphamide
8
fludarabine
7
pembrolizumab
6
aldesleukin
4
Interleukin-2
3
spartalizumab
2
fludarabine phosphate
2
entinostat
2
Vorinostat
2
Trastuzumab
2
Nivolumab
2
Erlotinib Hydrochloride
2
Biopsy
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tislelizumab
1
tipifarnib
1
prexasertib
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
enzalutamide
1
cemiplimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
abiraterone
1
Tomography, X-Ray Computed
1
Thalidomide
1
Technetium-99
1
Taxes
1
SRA737
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
nanocis
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled